Efficacy of Ocrelizumab in Autoimmune Encephalitis

Phase 2TerminatedNCT03835728

University of Texas Southwestern Medical Center3 enrolled

Overview

This pilot study is a randomized, double-blind, placebo controlled study of the efficacy of ocrelizumab in autoimmune encephalitis. Subjects with new diagnosis of autoimmune encephalitis will be invited to enroll in this study. Subjects will be randomized to receive ocrelizumab (an anti-CD20 therapy) or matched placebo, and will undergo three infusions over a six month period. Subjects will complete clinical visits over the study period, during which safety monitoring and neuropsychological assessments will be performed to assess for signs of clinical worsening from encephalitis. The primary outcome of this study is the proportion of patients who fail to complete the twelve month period without clinical worsening, as defined by the protocol. Subjects who experience early clinical worsening during the study may be offered open-label treatment with ocrelizumab at the discretion of the investigators.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Autoimmune Encephalitis

Interventions

Subjects will be randomized in a 1:1 fashion to receive infusion of Ocrelizumab (2 doses at 300 mg and 1 dose at 600 mg) or matched placebo. The 2 300 mg doses will be administered at day 2 and day 14. The 600 mg dose will be administered during the 6 month visit. The drug will be administered via infusion three times throughout the trial period: after the initial screening, at two weeks from initial infusion, and at 6 months.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age 18 or greater 2. Able to obtain informed consent from patient or appropriate designee 3. Possible autoimmune encephalitis as defined by Table 1: 1. Reasonable exclusion of alternative causes 2. Subacute onset (\< 3 months) of memory deficits, altered consciousness, and/or psychiatric symptoms 3. One or more of the following: * CSF (cerebrospinal fluid) pleocytosis (\>5 cells/µl corrected, if necessary, for traumatic lumbar puncture) * EEG (electroencephalogram) with epileptiform or focal slow wave abnormalities involving temporal lobes * Brain abnormalities on T2/FLAIR MRI restricted to the mesial temporal (limbic) lobes * Associated dyskinesias (faciobrachial dystonic movements or orofacial dyskinesias) 4. Completed initial treatment with iv steroids (at least 3000mg solumedrol) and plasma exchange (at least 3 exchanges) within the past 8 weeks 5. Presence of one (or more) of the following autoantibodies in serum or CSF * NMDA receptor * LGI1 * CASPR2 * DPPX Exclusion Criteria: 1. Prior immunosuppression treatment in past year (other than steroids, intravenous immunoglobulin and plasma exchange) 2. Active malignancy requiring chemotherapy 3. Pregnancy 4. Evidence of active hepatitis or tuberculosis infection 5. Medical condition that (in investigators opinion) precludes the use of ocrelizumab

Outcomes

Primary Outcomes

Number of Participants Who Had Clinical Worsening

The number of participants who had clinical worsening within 12 months.

Time frame: 12 months

Secondary Outcomes

Time to Treatment Failure

Definition of clinical worsening (treatment failure): 1. Clinician or patient/caregiver perception of clinical decline 2. Worsening of patient/family reported IADL (by one point or more) 3. One of the following additional features: * Significant worsening of Texas Functional Living Scale (by ≥ 5 T points, 0.5 st deviation) * Other clinical worsening leading to hospitalization

Time frame: 12 months

Change in TFLS T-score (Texas Functional Living Scale) Score at 6 Months

Change in TFLS T-score (Texas Functional Living Scale) scores at 6 months compared to baseline. - A performance-based measure of functional competence designed to assess instrumental activities of daily living (e.g., managing money) that are thought to be more susceptible to cognitive change than basic activities of daily living (e.g., dressing). Content and Structure: The TFLS is comprised of 24 items divided into four subscales assessing abilities related to Time, Money and Calculation, Communication, and Memory. Many items provide a range of possible points allowing the instrument to account for the varying levels of functioning that may be observed in clinical populations. Total raw score ranges between 0 and 50 with standardized T-score values between 20 and 66. The higher the score, the better the performance. Change in TFLS T-score was used in this study

Time frame: Baseline, 6 month

Change in TFLS T Score (Texas Functional Living Scale) Score at 12 Months

Change in TFLS T-score (Texas Functional Living Scale) scores at 12 months compared to baseline. - A performance-based measure of functional competence designed to assess instrumental activities of daily living (e.g., managing money) that are thought to be more susceptible to cognitive change than basic activities of daily living (e.g., dressing). Content and Structure: The TFLS is comprised of 24 items divided into four subscales assessing abilities related to Time, Money and Calculation, Communication, and Memory. Many items provide a range of possible points allowing the instrument to account for the varying levels of functioning that may be observed in clinical populations. Total raw score ranges between 0 and 50 with standardized T-score values between 20 and 66. The higher the score, the better the performance. Change in TFLS T-score was used in this study

Time frame: Baseline, 12 months